Summary
Background Antimicrobial resistance (AMR) is a global health problem. However, quantitative evaluation of its disease burden is challenging. This study aimed to estimate the disease burden of bloodstream infections (BSIs) caused by major antimicrobial-resistant bacteria in Japan between 2015 and 2018 in terms of disability-adjusted life-years (DALYs).
Methods We estimated the DALYs of BSIs caused by the six major antimicrobial-resistant bacteria in Japan by utilising comprehensive national surveillance data of all routine bacteriological test results from more than 1,400 hospitals between 2015 and 2018. We modified the methodology of a previous study by Cassini and colleagues to enable comparison of our results with those in other countries.
Results We estimated that 135.8 (95% uncertainty interval [UI] 128.6-142.9) DALYs per 100,000 population was attributable to BSIs caused by the six antimicrobial-resistant bacteria in 2018. Staphylococcus aureus (MRSA), fluoroquinolone-resistant Escherichia coli (FQREC), and third-generation cephalosporin-resistant E. coli (3GREC) accounted for 88.6% of the total. The burden did not decrease during the study period and was highest in people aged 65 years or older.
Conclusion Our results revealed for the first time the disease burden of BSIs caused by six major antimicrobial-resistant bacteria in Japan. The estimated disease burden associated with AMR in Japan is substantial and has not begun to decrease. Notably, the burden from FQREC and 3GREC has increased steadily and that from MRSA is larger than EU/EEA area, whereas that from other bacteria was comparatively small. Our results are expected to provide useful information for healthcare policymakers for prioritising interventions for AMR.
Funding Ministry of Health, Labour and Welfare research grant (20HA2003); Japan Agency for Medical Research and Development Research Program on Emerging and Re-emerging Infectious Diseases (JP19fk0108061)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ministry of Health, Labour and Welfare research grant (20HA2003); Japan Agency for Medical Research and Development Research Program on Emerging and Re-emerging Infectious Diseases (JP19fk0108061)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient identifiers were de-identified by each hospital before the data were submitted to JANIS. Approval for extraction and use of the data was granted by the Ministry of Health, Labour and Welfare (0424e1).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study will be made available by the corresponding author upon reasonable request.
